Back to results
US 2020/0270608 A1Published application
Modulation of huntingtin expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsGene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
Claims16
A single-stranded modified oligonucleotide consisting of 18 linked nucleosides and having:
- a gap segment consisting of eight linked deoxynucleosides;
- a 5′ wing segment consisting of five linked nucleosides;
- and
- a 3′ wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment;
- wherein each nucleoside of each wing segment comprises a 2′O-methoxyethyl sugar;
- and
- wherein the nucleobase sequence of the oligonucleotide consists of the sequence recited in SEQ ID NO:
- 35,
- or a pharmaceutically acceptable salt thereof.
7 more elements
Dependencies are inferred from the claim text.